Deloitte Announces New Additions To Its ConvergeHEALTH Suite Of Life Sciences End To End Evidence Life Cycle Management Solutions

BOSTON, April 5, 2016 /PRNewswire/ -- Deloitte today announced new components and capabilities within its ConvergeHEALTH Miner Solution suite, designed to help life science companies to unlock the full potential of data generated across the evidence life cycle from research through clinical trials to real world evidence. These solutions, coupled with data and software tools from third parties, help life sciences companies manage health care's shift toward a value based, personalized paradigm where innovation and outcomes are rewarded.

The newest Miner components, Research Trust, Data Asset Explorer and Cohort Integrator, help life sciences companies leverage data in new ways to rapidly translate new breakthroughs into clinical practice. The components also help these companies understand the value of those innovations in a real world setting necessities in value-based care. Solutions like Miner along with partnerships and efficient operating models help life sciences companies meet their needs for new and better data management, analytics and workflow solutions to support research, product development, market access and distribution. 

Research Trust extends ConvergeHEALTH's Data Trust platform and enables data integration from internal and external data assets to support downstream analytic and visualization applications in translational research. Research Trust is BRIDG 4.0 compliant and hence supports integration and aggregation of CDISC SDTM 3.1.2 and SEND 1.2 data sets. The patient-centric model is also OMOP 5.0 compliant which creates a unique data store containing both controlled and real world data. ConvergeHEALTH by Deloitte has long supported open and community innovation, and has embedded leading open source tools into the Miner solution including tranSMART, OMOP and CDISC. 

"It is great to see Deloitte's continued investment in open data and open science.  Through collaborative models such as this, we will see significantly faster discovery further advancing science and inevitably benefiting the patient," said Keith Elliston, CEO of the tranSMART Foundation.

Data Asset Explorer (DAE) addresses business needs in knowledge management and collaboration across the entire enterprise, from R&D through real world evidence, enabling users to access and manage all their data and evidence assets, including external partnerships and data sets. This allows the organization to better formulate and refine research hypotheses, develop value propositions for their products in real world settings, and identify more efficient commercial and market access strategies. Workflow features in DAE support enterprise governance and compliance requirements and generate performance reports on data asset utilization of data assets across the enterprise.

Cohort Integrator enables management of cohorts of patients across various use cases by supporting researchers and analyst workflows. It also allows for reuse, sharing and tracing of cohort(s) and inclusion/exclusion criteria across third party analytic and visualization applications.

"Deloitte is committed to investing in integrated solutions that bring together technologies from our software and data partners, coupled with solutions from ConvergeHEALTH, to bring integrated, enterprise approaches to our life sciences clients as they shift towards the deployment of new business and operating models that require end to end evidence platforms," said Brett J. Davis, principal, Deloitte Consulting LLP, and general manager, ConvergeHEALTH by Deloitte. "The shift to value based, personalized health care is a team sport that requires many different components to come together and we are committed to supporting our clients on this transformational journey."

Several of these solution components will be presented at Bio-IT World Conference & Expo in Boston at Deloitte's booth number 353, as well as in a joint presentation with Amgen. David Hardison Ph.D., vice president health sciences ConvergeHEALTH by Deloitte, and George Seegan, Ph.D., Amgen R&D Informatics, will present "Accelerating Insights in Translational Research: Self-Service Analytics and Visualizations at Amgen." This cloud-based, information integration factory delivers relevant data on demand to researchers through an easy to use, extensible analytics and visualization portal. 

About Deloitte Consulting LLP
Deloitte helps organizations grow their businesses and enhance value by identifying actionable insights. More than 23,000 professionals provide a broad range of capabilities across human capital, strategy and operations, innovation and technology that are aligned to the particular needs of specific sectors, businesses and organizations. Deloitte provides clients with leading business insights that can help generate a tangible and measurable impact.

About ConvergeHEALTH by Deloitte 
ConvergeHEALTH brings powerful, demonstrated analytics platforms and data models. We use advanced proprietary and open source analytics, content and benchmarks through collaboration with industry leaders and deep experiences from Deloitte's life sciences and health care consulting practice to help our clients survive and thrive in the new paradigm of value-based, personalized medicine. For more information, visit www.converge-health.com.

As used in this document, "Deloitte" means Deloitte Consulting LLP, a subsidiary of Deloitte LLP. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting.

Logo - http://photos.prnewswire.com/prnh/20120803/MM52028LOGO-a

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/deloitte-announces-new-additions-to-its-convergehealth-suite-of-life-sciences-end-to-end-evidence-life-cycle-management-solutions-300246255.html

SOURCE Deloitte